Alnylam Pharmaceuticals, Inc.（ALNY）の株式分析ALNYAlnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Alnylam Pharmaceuticals is currently a hold. The stock is priced at $224.03, with a forward P/E ratio of 19.685, indicating potential for growth. However, the RSI is at 37.57, suggesting it is nearing oversold territory, which could indicate a rebound is possible. The main risk is the recent 44.02% year-to-date decline, reflecting significant market skepticism about its growth trajectory.

18 analysts cover ALNY: 13 rate it Buy, 4 Hold and 1 Sell. The average price target is 479.53.